We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $168M
1-Year Est. Return 60.36%
This Fund
S&P 500
This Quarter Est. Return
+12.82%
1 Year Est. Return
+60.36%
3 Year Est. Return
+143.93%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$221M
AUM Growth
+$8.65M
Cap. Flow
-$6.33M
Cap. Flow %
-2.87%
Top 10 Hldgs %
71.57%
Holding
93
New
9
Increased
15
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$2.91M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$2.47M
3
LENZ
LENZ Therapeutics
LENZ
+$2.23M
4
ALKS icon
Alkermes
ALKS
+$1.46M
5
LQDA icon
Liquidia Corp
LQDA
+$1.33M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$4.2M
2
JAAA icon
Janus Henderson AAA CLO ETF
JAAA
+$2.85M
3
VRNA
Verona Pharma
VRNA
+$2.44M
4
ARDX icon
Ardelyx
ARDX
+$2.42M
5
OABI icon
OmniAb
OABI
+$2.36M

Sector Composition

Rank Sector Weight
1 Healthcare 31.49%
2 Materials 24.07%
3 Financials 19.36%
4 Communication Services 9.05%
5 Industrials 1.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
26
Alkermes
ALKS
$8.82B
$1.4M 0.64%
+49,000
New +$1.46M
VRDN icon
27
Viridian Therapeutics
VRDN
$2.13B
$1.28M 0.58%
91,483
+61,483
+205% +$834K
CLOZ icon
28
Panagram BBB-B CLO ETF
CLOZ
$773M
$1.28M 0.58%
47,807
– –
BMY icon
29
Bristol-Myers Squibb
BMY
$127B
$1.25M 0.57%
27,000
+8,000
+42% +$393K
RHP icon
30
Ryman Hospitality Properties
RHP
$8.4B
$1.18M 0.54%
12,000
– –
LQDA icon
31
Liquidia Corp
LQDA
$7.67B
$1.12M 0.51%
+90,000
New +$1.33M
JNJ icon
32
Johnson & Johnson
JNJ
$635B
$1.06M 0.48%
6,922
+6,000
+651% +$922K
MYGN icon
33
Myriad Genetics
MYGN
$530M
$956K 0.43%
180,000
+20,000
+13% +$118K
ABBV icon
34
AbbVie
ABBV
$458B
$935K 0.42%
5,037
– –
MREO
35
Mereo BioPharma
MREO
$45.9M
$865K 0.39%
319,337
– –
CTVA icon
36
Corteva
CTVA
$59.7B
$824K 0.37%
11,051
– –
MSFT icon
37
Microsoft
MSFT
$2.84T
$796K 0.36%
1,600
– –
SLDB icon
38
Solid Biosciences
SLDB
$771M
$791K 0.36%
162,440
+30,440
+23% +$108K
KMB icon
39
Kimberly-Clark
KMB
$36.4B
$774K 0.35%
6,000
– –
COLL icon
40
Collegium Pharmaceutical
COLL
$1.14B
$695K 0.32%
23,511
-14,962
-39% -$427K
DD icon
41
DuPont de Nemours
DD
$18.6B
$646K 0.29%
7,503
– –
IBM icon
42
IBM
IBM
$202B
$631K 0.29%
2,142
– –
AXSM icon
43
Axsome Therapeutics
AXSM
$12.4B
$626K 0.28%
+6,000
New +$635K
AUTL
44
Autolus Therapeutics
AUTL
$386M
$616K 0.28%
270,000
-150,000
-36% -$248K
MDLZ icon
45
Mondelez International
MDLZ
$77.7B
$607K 0.28%
9,000
– –
MDGL icon
46
Madrigal Pharmaceuticals
MDGL
$12.6B
$605K 0.27%
+2,000
New +$596K
RCUS icon
47
Arcus Biosciences
RCUS
$3.57B
$570K 0.26%
70,000
+58,000
+483% +$495K
HELP
48
Cybin Inc
HELP
$472M
$561K 0.25%
66,880
– –
CNQ icon
49
Canadian Natural Resources
CNQ
$96.9B
$528K 0.24%
16,800
– –
AAPL icon
50
Apple
AAPL
$4.89T
$512K 0.23%
2,494
– –
1
2
3 4

Similar funds

DI
Disciplined Investors Waco, Texas $168M AUM 23.6% 1-Year Est. Return
WFS
Widmann Financial Services Bowie, Maryland $168M AUM 24.36% 1-Year Est. Return
CCG
Catalina Capital Group Torrance, California $168M AUM 16.69% 1-Year Est. Return
7CM
7G Capital Management New York $168M AUM 45.68% 1-Year Est. Return
MAG
Meadowbrook Advisors Group Bedminster, New Jersey $168M AUM
PFA
Presper Financial Architects Akron, Ohio $168M AUM 12.94% 1-Year Est. Return
CW
Code Waechter Tampa, Florida $168M AUM 15.56% 1-Year Est. Return
IWA
Integrity Wealth Advisors Ventura, California $168M AUM 18.33% 1-Year Est. Return

David M. Knott Jr's Q2 2025 Portfolio in Review

As of Q2 2025, David M. Knott Jr held 93 positions worth $221M, up 4.1% from $212M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

David M. Knott Jr's Q2 2025 filing shows 9 new, 15 increased, 13 reduced and 8 closed positions. Its largest new stake was BridgeBio Pharma: 80,000 shares worth $3.45M. The largest sale was Pfizer, an estimated $4.2M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 33% a quarter earlier, followed by Materials and Financials.

  • David M. Knott Jr's largest Q2 2025 buy was BridgeBio Pharma: 80,000 shares worth $3.45M.
  • David M. Knott Jr added most to Syndax Pharmaceuticals in Q2 2025, an estimated $2.47M increase.
  • David M. Knott Jr's biggest Q2 2025 reduction was Pfizer, cutting an estimated $4.2M.
  • David M. Knott Jr fully exited Ardelyx in Q2 2025, selling an estimated $2.42M.
  • David M. Knott Jr's ten largest holdings make up 72% of its $221M portfolio in Q2 2025.
  • David M. Knott Jr opened 9 new positions and closed 8 in Q2 2025.
  • David M. Knott Jr's portfolio value rose 4.1% quarter-over-quarter to $221M.

Based on David M. Knott Jr's 13F filing for Q2 2025, filed 11 Aug 2025.